Core Viewpoint - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases, with significant revenue growth driven by innovative treatments like Livmarli and bile acid drugs [1][6]. Financial Performance - Mirum reported a 50% increase in revenues for the fourth quarter, driven by strong sales of Livmarli and bile acid drugs, despite incurring a net loss [3][6]. - The company has a market capitalization of approximately $4.77 billion, indicating its size and market presence [5][6]. Stock Performance - Currently, MIRM's stock is priced at $92.22, reflecting a 15.10% decrease, with fluctuations between $90.26 and $100.19 on the trading day [4][6]. - Over the past year, the stock reached a high of $107.41 and a low of $36.88, indicating significant volatility [4]. Analyst Outlook - RBC Capital set a price target of $128 for MIRM, suggesting a potential upside of about 36% from its trading price of $94.14 at the time [2].

Core Insights - Mirum Pharmaceuticals (MIRM) shares increased by 7.1% following the announcement of strong preliminary results for Q4 and full-year 2025, which boosted investor confidence [1][6] Financial Performance - Preliminary net product sales for Mirum in 2025 were approximately $520 million, exceeding the management's guidance of $500-$510 million provided in November 2025 [2][6] - Estimated net product sales for Livmarli were around $359 million for 2025, while Cholbam and Ctexli contributed approximately $161 million [4] - For Q4 2025, estimated net product sales were about $149 million, including $106 million from Livmarli and around $43 million from Cholbam and Ctexli [5] 2026 Sales Outlook - Mirum forecasts net product sales of approximately $630-$650 million for 2026 [6][7] - The company is conducting a phase III study for Livmarli aimed at treating pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [7] Pipeline Developments - Mirum's lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data from the VISTAS study anticipated in Q2 2026 [8] - A definitive agreement to acquire Bluejay Therapeutics was announced in December 2025, which will enhance Mirum's portfolio in rare liver diseases [9] - A phase II study has been initiated for MRM-3379, a PDE4D inhibitor targeting Fragile X syndrome [10]

Core Viewpoint - Mirum Pharmaceuticals is experiencing significant commercial growth and positive market response, reflected in its stock performance and future prospects [2][5]. Group 1: Company Overview - Mirum Pharmaceuticals is a biopharmaceutical company based in Foster City, California, focusing on therapies for rare liver diseases [1]. - The company has a market capitalization of approximately $4.42 billion, indicating its substantial presence in the biopharmaceutical industry [4]. Group 2: Stock Performance - The stock price of Mirum is currently $89.50, reflecting an increase of approximately 3.38% with a change of $2.93 [2]. - The stock has fluctuated between a low of $82 and a high of $90.07 today, with the latter being its highest price over the past year [3]. - The lowest price for MIRM in the past year was $36.88, showcasing substantial growth [3]. Group 3: Market Sentiment - Robert W. Baird has set a price target of $95 for NASDAQ:MIRM, indicating a potential upside of approximately 6.15% [1][5]. - The trading volume for MIRM is 1,229,452 shares, suggesting active investor interest and engagement [4].